Return to Listing

6 result(s) for Melanoma

PI Name Protocol # Title
Sancy Leachman IRB00010561 War on Melanoma: Enlisting a cohort of melanoma survivors and their families
Matthew Taylor IRB00011804 A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
Matthew Taylor STUDY00015298 [NCI CIRB] EA6134: A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma
Matthew Taylor STUDY00015661 [NCI CIRB] S1404: A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma
Matthew Taylor STUDY00016225 IMCgp100-201: A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients with Advanced Melanoma
John Vetto STUDY00017104 DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080